Shuttle Pharma Nears 50% Enrollment in Phase 2 Trial of Ropidoxuridine for Glioblastoma with Promising Tolerability and Completion Rates

Shuttle Pharmaceuticals Holdings, Inc. , a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer pati...

May 09, 2025 | Friday | News
Aspen Neuroscience Reports Positive 6-Month Data for ANPD001 in Parkinson’s Disease Ahead of IAPRD 2025 Presentation

ANPD001 was well tolerated with no major safety issues in low-dose cohort Patients showed early improvements in patient-reported and clinician-re...

May 08, 2025 | Thursday | News
Theriva Biologics Reports Positive Phase 2b Data for VCN-01 in Metastatic Pancreatic Cancer

- Patients treated with VCN-01 (zabilugene almadenorepvec) plus standard gemcitabine/nab-paclitaxel chemotherapy had increased overall survival, progress...

May 08, 2025 | Thursday | Reports
BioAegis Launches Global 600-Patient Phase 2 Trial of rhu-pGSN to Treat ARDS and Advance Inflammation-Modulating Therapies

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...

May 07, 2025 | Wednesday | News
AGC Biologics Joins Hands with South Korea’s Novelty Nobility for Multisite Bispecific Antibody Project

Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...

May 06, 2025 | Tuesday | News
Can-Fite Secures $175M to Advance Oral A3AR Therapies into Phase III for Liver Cancer and Psoriasis

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases, toda...

May 06, 2025 | Tuesday | News
Recursion Reports Promising Early Results from Phase 2 TUPELO Trial of REC-4881 in Familial Adenomatous Polyposis

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of d...

May 05, 2025 | Monday | News
Chengdu Origen and Vanotech Dose First Patient in Phase 1 Trial of KH658 Gene Therapy for Wet AMD

Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced  the first patient dosed ...

May 05, 2025 | Monday | News
Crown Bioscience Extends Exclusive Partnership with NEXT Oncology to Advance Translational Cancer Research

Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corp...

May 02, 2025 | Friday | News
Genmab to Submit sBLA for Epcoritamab Combo in Relapsed or Refractory Follicular Lymphoma Following Strong Phase 3 Data

Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE®...

May 02, 2025 | Friday | News
EU Recommends Approval of Fixed-Duration Calquence Regimen for Untreated Chronic Lymphocytic Leukaemia

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has ...

May 01, 2025 | Thursday | News
Addex Therapeutics and Sinntaxis Partner to Advance Dipraglurant for Brain Injury Recovery

Addex Therapeutics  a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neu...

May 01, 2025 | Thursday | News
Nuvalent Publishes First-Ever Crystal Structure of ROS1 G2032R, Supporting Rational Design of Zidesamtinib

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinical...

May 01, 2025 | Thursday | News
Innovent Biologics Doses First Patient in Global Phase 1 Trial of IBI3020, First-in-Class Dual-Payload CEACAM5 ADC

Innovent Biologics, Inc. ("Innovent"), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for t...

May 01, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close